Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy.
Journal: International journal of hematology
Published: April 14, 2026
Cardiotoxicity of T cell immunotherapies.
Journal: Nature reviews. Cardiology
Published: February 08, 2026
A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity.
Journal: Haematologica
Published: May 14, 2025
IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation.
Journal: Cell reports
Published: February 28, 2025
Allogeneic chimeric antigen receptors (CARs) as an "off-the-shelf" therapy in multiple myeloma.
Journal: Immunotherapy
Published: February 17, 2025
Metabolic regulation of RNA methylation by the m6A-reader IGF2BP3.
Journal: bioRxiv : the preprint server for biology
Published: November 18, 2024
IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.
Journal: Cancers
Published: July 29, 2023
Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia.
Journal: Blood advances
Published: July 05, 2023
The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis.
Journal: Leukemia
Published: February 19, 2021
Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.
Journal: Scientific reports
Published: December 13, 2020
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Journal: British journal of haematology
Published: April 16, 2017
Last Updated: 09/26/2026